| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥141.7B | ¥121.2B | +17.0% |
| Operating Income | ¥8.5B | ¥12.9B | -34.0% |
| Ordinary Income | ¥5.5B | ¥10.1B | -45.4% |
| Net Income | ¥0.9B | ¥7.1B | -87.0% |
| ROE | 2.5% | 20.5% | - |
FY2025 results: Revenue ¥141.7B (YoY +17.0%), Operating Income ¥8.5B (YoY -34.0%), Ordinary Income ¥5.5B (YoY -45.4%), Net Income ¥0.9B (YoY -87.0%). The company achieved strong revenue growth of 17.0%, marking robust top-line expansion. However, profitability deteriorated significantly across all profit metrics, with net income declining 87.0% to ¥0.9B. This revenue up/profit down pattern reflects margin compression and increased financial costs. Gross profit reached ¥19.0B with a margin of 13.4%, while operating margin contracted to 6.0% from prior year levels. Operating cash flow remained healthy at ¥10.5B, up 25.3% YoY, demonstrating cash generation capability at 3.76 times net income. The company maintains forward guidance projecting revenue of ¥165.0B and operating income of ¥15.0B, implying expected margin recovery.
Revenue increased 17.0% to ¥141.7B, driven by business expansion in the hospice care sector. The top-line growth reflects capacity additions and service volume increases. On the profit side, gross profit reached ¥19.0B but gross margin remained compressed at 13.4%, indicating cost pressures or pricing challenges. SG&A expenses totaled ¥10.5B, representing 7.4% of revenue and including ¥1.6B in salaries and ¥0.6B in goodwill amortization. Operating income declined 34.0% to ¥8.5B, resulting in an operating margin of 6.0%, down from approximately 10.6% in the prior year. The substantial gap between operating income (¥8.5B) and ordinary income (¥5.5B) of ¥3.0B is attributable to non-operating expenses of ¥4.7B, predominantly interest expense of ¥4.6B, which represents 3.3% of revenue. This heavy interest burden reflects the company's elevated debt load, with long-term loans of ¥32.5B and total interest-bearing debt of ¥38.5B. The effective tax rate reached approximately 49.9%, contributing to the sharp decline in net income to ¥0.9B from ¥7.1B. No material extraordinary items were recorded. This represents a revenue up/profit down pattern, where strong top-line growth was offset by margin compression, elevated financial costs, and high tax burden.
[Profitability] ROE 2.5% declined significantly from prior levels, reflecting the sharp contraction in net income relative to equity base. Operating margin of 6.0% compressed substantially from approximately 10.6% YoY, driven by gross margin pressure at 13.4% and elevated SG&A ratio of 7.4%. Net profit margin fell to 0.6% due to interest burden of 3.3% of revenue and effective tax rate of 49.9%. [Cash Quality] Cash and deposits reached ¥20.1B, up 31.9% YoY, providing coverage of 3.35 times short-term debt of ¥6.0B and 0.59 times current liabilities of ¥34.1B. Operating cash flow of ¥10.5B exceeded net income by 11.6 times, confirming strong cash-backed earnings quality. Working capital management showed accounts receivable of ¥22.8B, representing 58.9 days sales outstanding based on current revenue run rate. [Investment Efficiency] Asset turnover of 0.75 reflects a capital-intensive business model with property, plant and equipment of ¥128.2B representing 67.8% of total assets. CapEx of ¥23.7B substantially exceeded depreciation of ¥5.2B, yielding a capital intensity ratio of 4.53, indicating aggressive growth investment. [Financial Health] Equity ratio of 19.4% remains below the 30% threshold typically considered healthy, reflecting high leverage. Current ratio of 133.6% provides adequate short-term liquidity. Debt-to-equity ratio of 4.15 is elevated, with interest-bearing debt of ¥38.5B against equity of ¥36.8B. Interest coverage ratio based on EBITDA (operating income plus D&A of ¥13.7B) over interest expense (¥4.6B) stands at 2.98, indicating modest but acceptable debt service capacity.
Operating cash flow of ¥10.5B represents 11.6 times net income of ¥0.9B, confirming strong cash generation despite profit compression. The operating CF subtotal before working capital changes reached ¥16.6B, with working capital providing a net inflow, including a ¥3.4B decrease in receivables that contributed positively. Income taxes paid of ¥3.7B and interest paid of ¥4.7B consumed ¥8.4B of operating cash flow. Investing cash flow of negative ¥5.1B was driven by capital expenditures of ¥23.7B, partially offset by asset disposals or other investing inflows of approximately ¥18.6B. Free cash flow of ¥5.3B (operating CF minus investing CF) demonstrates positive cash generation after investments. Financing cash flow of negative ¥0.5B reflected minimal activity, with negligible share repurchases and likely included some debt servicing. The net result was a ¥4.9B increase in cash position to ¥20.1B, representing 31.9% growth. The company's ability to generate operating CF of 1.23 times operating income (adjusted for D&A) indicates healthy conversion, while the CapEx-to-depreciation ratio of 4.53 signals an investment phase focused on capacity expansion. Cash coverage of short-term liabilities at 0.59 times total current liabilities requires monitoring, though the 3.35 times coverage of short-term debt specifically provides reasonable near-term debt servicing capacity.
Ordinary income of ¥5.5B versus operating income of ¥8.5B shows a non-operating net loss of approximately ¥3.0B, consisting primarily of interest expense of ¥4.6B partially offset by non-operating income of ¥1.7B. Non-operating income represents 1.2% of revenue and includes interest income of negligible amount and other income of ¥0.2B, with the remainder comprising equity method gains or financial income. The interest burden of ¥4.6B represents 54.1% of operating income, substantially eroding operating-level profitability. This financial cost structure reflects the company's debt-financed growth model with interest-bearing debt of ¥38.5B. The gap between profit before tax of ¥5.5B and net income of ¥0.9B is explained by income tax expense of ¥2.8B, yielding an effective tax rate of approximately 49.9%, significantly above the statutory corporate tax rate. This elevated tax burden warrants scrutiny regarding non-deductible expenses or tax adjustments. Operating cash flow of ¥10.5B substantially exceeds net income, indicating healthy earnings quality from a cash perspective. Comprehensive income of ¥2.8B exceeds net income of ¥0.9B by ¥1.9B, suggesting positive other comprehensive income items not flowing through the P&L. The combination of high interest burden, elevated tax rate, and cash generation exceeding reported earnings suggests that while operational cash quality is sound, financial structure and tax efficiency present significant headwinds to reported profitability.
Progress rate versus full-year guidance shows revenue at 85.9% (¥141.7B of ¥165.0B target), operating income at 56.7% (¥8.5B of ¥15.0B target), and ordinary income at 55.0% (¥5.5B of ¥10.0B target) of forecast. Assuming this represents full-year actual results rather than partial-year progress, the company has fallen short of initial guidance, with operating income and ordinary income missing targets by 43.3% and 45.0% respectively. The forecast implies a projected net income of ¥6.0B, compared to actual of ¥0.9B, representing an 85.0% shortfall. The guidance assumes EPS of ¥71.20 versus actual basic EPS of ¥33.07, confirming the significant profit miss. Key drivers of the variance include lower-than-expected operating margin (6.0% actual versus implied 9.1% in guidance) and likely higher interest costs or tax burden than originally anticipated. The company maintains zero dividend forecast (¥0.00) despite actual dividend of ¥15.0, suggesting a conservative approach to shareholder returns pending profit recovery. The forecast notes indicate that forward-looking statements are based on currently available information and certain assumptions, with actual results potentially varying significantly due to various factors. Recovery to guidance levels would require substantial margin improvement and cost reduction in subsequent periods.
Annual dividend per share stands at ¥15.0, with payout ratio calculated at 19.2% based on reported metrics, though calculation versus net income of ¥0.9B suggests an approximate 45.5% payout ratio. The company's forecast indicates zero dividend (¥0.0) going forward, representing a potential dividend suspension pending profit recovery. Share repurchases were negligible at approximately ¥0.0B based on financing cash flow data. Total shareholder return ratio, combining dividends and buybacks, approximates the dividend payout ratio of 19.2% to 45.5% depending on calculation basis. Free cash flow of ¥5.3B provides coverage of 4.23 times the implied dividend obligation, indicating financial capacity to sustain dividends from cash generation despite profit compression. However, the zero dividend forecast suggests management prudence in conserving cash during the investment phase. The discrepancy between current dividend payment and zero forward guidance warrants clarification, as it may reflect fiscal year-end timing or policy revision.
Financial leverage risk stands as the primary concern, with debt-to-equity ratio of 4.15 and interest-bearing debt of ¥38.5B against equity of ¥36.8B. Interest coverage of 1.84 times (EBIT/interest) provides limited cushion, and any operating deterioration or interest rate increase could threaten debt servicing capacity. The equity ratio of 19.4% leaves minimal buffer for asset value declines. Margin compression risk is evident in the gross margin of 13.4% and operating margin contraction to 6.0% from prior 10.6%. This reflects pricing pressure, cost inflation, or operational inefficiency. Without margin recovery, the company cannot achieve profit targets despite revenue growth. Sustaining current gross margins under cost pressure or competitive dynamics could further erode profitability. Capital investment execution risk emerges from CapEx of ¥23.7B, representing 16.7% of revenue and 4.53 times depreciation. This aggressive expansion requires successful facility ramp-up, occupancy achievement, and returns realization. Delays in investment payback, lower-than-expected utilization, or regulatory challenges could impair cash flow generation and leave the company overleveraged relative to earnings power.
[Industry Position] (Reference - Proprietary Analysis) The company operates in the healthcare services sector, specifically hospice and palliative care. Historical data indicates revenue growth of 17.0% in FY2025, demonstrating expansion pace. Limited benchmark data is available, but the analysis suggests the following relative positioning: Profitability metrics show operating margin of 6.0% and net profit margin of 0.6%, which appear compressed relative to typical healthcare service providers that often achieve double-digit operating margins in mature operations. The company's ROE of 2.5% is substantially below typical healthcare service sector medians of 8-12%, reflecting both profit compression and high leverage. Financial Health indicators show equity ratio of 19.4%, which is below the healthcare services industry median range of 35-50%, indicating higher financial risk. The debt-to-equity ratio of 4.15 exceeds typical industry norms of 0.5-1.5, positioning the company at the aggressive end of leverage within its sector. Efficiency metrics include asset turnover of 0.75, consistent with capital-intensive healthcare facility operations, though the CapEx intensity of 16.7% of revenue suggests a growth investment phase rather than mature steady-state operations. The company's cash conversion, with operating CF exceeding net income by 11.6 times, demonstrates operational strength despite reported profit weakness. Industry context: Healthcare services companies in growth phases typically exhibit elevated CapEx and leverage, but generally maintain higher margins through reimbursement stability and operational leverage once facilities mature.
Strong revenue momentum of 17.0% growth demonstrates market demand for hospice services and successful capacity expansion, supported by robust operating cash flow generation of ¥10.5B that exceeds net income by 11.6 times, confirming underlying business model cash generation despite reported profit compression. The company's structural profitability challenge is evident in persistent gross margin pressure at 13.4% and elevated financial costs consuming 54.1% of operating income through ¥4.6B in interest expense, requiring either margin improvement through operational leverage or debt reduction to restore profitability to historical levels. The investment phase characteristics are pronounced, with CapEx of ¥23.7B representing 4.53 times depreciation and driving facility expansion, creating a multi-year inflection point where successful ramp-up and occupancy achievement could materially improve returns, though execution risk remains elevated given the 43.3% operating income shortfall versus guidance.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.